

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

ICN PHARMACEUTICALS INC
Form DEFA14A
May 15, 2001

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934

Filed by the Registrant [X]

Filed by a Party other than the Registrant []

Check the appropriate box:

[] Preliminary Proxy Statement

[] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))

[] Definitive Proxy Statement

[X] Definitive Additional Materials

[] Soliciting Material Pursuant to Section 240.14a-12

ICN Pharmaceuticals, Inc.

(Name of Registrant as Specified in its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

[] Fee paid previously with preliminary materials.

[] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Following is a transcript of a video posted on the "2001 Annual Meeting"
section of ICN Pharmaceuticals, Inc.'s website, www.icnpharm.com, on or
about May 14, 2001:

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

Kim Campbell's video statement for the Website

I am very pleased to be standing for election to ICN's Board of Directors. To me, it is an opportunity to join a dynamic company with a strong track record and really enormous potential. It is a critical and important time for ICN and I hope to be a valuable and active participant in achieving the company's business objectives. I am particularly impressed with ICN's research and development program with an exciting pipeline of drugs to meet the world's health needs.

I have been interested and involved in health issues from both the political and academic side of my life. As a member of the Canadian Governments, I have been involved in public policy issues relating to healthcare. And in particular, my involvement as Canada's Prime Minister, Attorney General and Defense Minister has brought me in the hotbed of strategic thinking which is so important in any modern corporate Board of Directors.

I just spent four years as Canada's Consul General in Los Angeles where I was able to develop my knowledge of international trade and particularly in working areas like the biotechnology industry where trade and research and development are such important components for developing the pharmaceutical industry. I hope to bring my very wide international contacts to play, to bear an understanding how to plan ICN future growth. It is a great company and I would like to be a part of it.